Cv rare disease

[anonymous]

Without x reps promoting will BMS follow suit?

Good point…already scaled back budgets. We still have contracted calls to Pfizer

 

[anonymous]

BMS not saying cv institutio,al reps are now true rare disease reps selling csmzyos. Anyone get a salary increase?
When will Cytokinetics hire us all

BMS talks out of both sides of their mouths. They want to say we are rare disease reps, but in the same breath say that 1 in 200 to 1 in 500 patients have oCHM (but 85% are not diagnosed or misdiagnosed). Rare disease is described as less than 200k patients in the USA. It is estimated over 700k Americans have oHCM......... SOOOOOO, BMS if you want us to prove to doctors that they are under-diagnosing or misdiagnosing (because these patients are either missed or caught in echo), stop calling us rare disease reps. oHCM is NOT a rare disease, and its essential that HCPs know that so they identify these patients sooner.

 

[anonymous]

Can someone tell me what the role of a Senior Theraputic Area Specialist, CV, Community actually does? The role description makes it seem like an MSL position versus a true front line sales rep position. Any guidance would be appreciated.

Its a sales rep position- not calling on hospitals- mainly cardio offices and high volume primary care/IM.

 

[anonymous]

BMS talks out of both sides of their mouths. They want to say we are rare disease reps, but in the same breath say that 1 in 200 to 1 in 500 patients have oCHM (but 85% are not diagnosed or misdiagnosed). Rare disease is described as less than 200k patients in the USA. It is estimated over 700k Americans have oHCM......... SOOOOOO, BMS if you want us to prove to doctors that they are under-diagnosing or misdiagnosing (because these patients are either missed or caught in echo), stop calling us rare disease reps. oHCM is NOT a rare disease, and its essential that HCPs know that so they identify these patients sooner.

So you’re open to a salary cut then? Buffoon

 

[anonymous]

It seems like you might be in denial or really buying into the narrative of our “growth”. We're falling short of our projected goals, which are extremely high, and many reps are struggling to earn their bonuses. They keep creating scenarios that don't reflect reality. If this drug is 1 in 500, the goals and expectations shouldn't be in double digits, especially without any Centers of Excellence in the territory. We're facing the same issues with IC and geographies like Zeposia, with changes happening every 5-6 months. BMS has struggled with their last four launches and seems to lack the expertise in launching rare disease and biologic drugs.

1/500 is not rare disease. That's a prevalence of 660,000. That's specialty sales. The upper limit of rare is 200,000.